The global pharmaceutical industry stands at a crucial juncture today. It is plagued by a peaking patent cliff, ever-increasing R&D costs, diminishing product pipelines, stringent approval systems and an increasing drift towards personalized medicines. The need of the hour is to help pharmaceutical companies evolve their existing business models, which will enable them to tackle challenges and ensure the growth of their organizations.